37 results on '"A. Alberola"'
Search Results
2. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine
3. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients
4. Lung cancer and treatment in elderly patients: The Achilles Study
5. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC
6. Genetic testing for chemotherapy in non-small cell lung cancer
7. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer
8. PD-004 Serum levels of vascular endothelial growth factor andepidermal growth factor receptor in advanced non-small cell lung cancer: Its correlation with clinical characteristics
9. PD-042 Induction (I) or consolidation (C) chemotherapy withdocetaxel (D) and gemcitabine (G) plus concomitant chemoradiotherapy (CT/TRT) with docetaxel and carboplatin (Cb) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Initial report of the randomized phase II trial SLCG 0008
10. P-561 14-3-3 sigma (σ) methylation (M) in pre-treatment serum DNAof cisplatin (cis)/gemcitabine (gem)-treated non-small-cell lung cancer (NSCLC)
11. PD-149 Epidermal growth factor receptor (EGFR)-activating mutations(mut) and response to gefitinib in lung adenocarcinomas
12. PD-026 The analysis of serum DNA concentration by means of hTERT quantification: A useful prognostic factor in advanced non-small cell lung cancer (NSCLC)
13. O-47 XPD polymorphisms identify a subset of non-small-cell lung cancer (NSCLC) patients (p) with poor survival with gemcitabine (gem)/cisplatin (cis)
14. E-62. Pharmacogenomics: Individualized therapy
15. P-206 Comorbidity assessment in frail patients with advanced non-small cell lung cancer (NSCLC) treated with low-dose of weekly paclitaxel (WP)
16. P-224 XPD polymorphisms in cisplatin (cis)/vinorelbine (vrb)-treated stage IV non-small-cell lung cancer (NSCLC) patients (p): genetic analysis of a Spanish Lung Cancer Group phase II trial
17. PD-004 Serum levels of vascular endothelial growth factor andepidermal growth factor receptor in advanced non-small cell lung cancer: Its correlation with clinical characteristics
18. PD-042 Induction (I) or consolidation (C) chemotherapy withdocetaxel (D) and gemcitabine (G) plus concomitant chemoradiotherapy (CT/TRT) with docetaxel and carboplatin (Cb) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Initial report of the randomized phase II trial SLCG 0008
19. P-561 14-3-3 sigma (σ) methylation (M) in pre-treatment serum DNAof cisplatin (cis)/gemcitabine (gem)-treated non-small-cell lung cancer (NSCLC)
20. PD-149 Epidermal growth factor receptor (EGFR)-activating mutations(mut) and response to gefitinib in lung adenocarcinomas
21. O-47 XPD polymorphisms identify a subset of non-small-cell lung cancer (NSCLC) patients (p) with poor survival with gemcitabine (gem)/cisplatin (cis)
22. E-62. Pharmacogenomics: Individualized therapy
23. P-224 XPD polymorphisms in cisplatin (cis)/vinorelbine (vrb)-treated stage IV non-small-cell lung cancer (NSCLC) patients (p): genetic analysis of a Spanish Lung Cancer Group phase II trial
24. Assessment of tubulin mutations in a phase II study of biweekly gemcitabine/paclitaxel (T) in advanced non-small-cell lung cancer (NSCLC)
25. Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer. Interim analysis of a Spanish Lung Cancer Group (SLCG) phase III trial
26. Navelbine: The European experience in non small cell lung carcinoma (NSCLC)
27. Assessment of tubulin mutations in a phase II study of biweekly gemcitabine/paclitaxel (T) in advanced non-small-cell lung cancer (NSCLC)
28. Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer. Interim analysis of a Spanish Lung Cancer Group (SLCG) phase III trial
29. 39 Six year follow up of the European Multicentre Randomised Study comparing Navelbine (NVB) alone vs NVB + Cisplatin (CDDP) vs Vindesine (VDS) + CDDP in 612 patients (pts) with advanced non-small cell lung cancer (NSCLC)
30. 243 Spanish lung cancer group randomized trial of preoperative chemotherapy (cisplatin either 50 mg/m2 or 100 mg/m2) in stage IIIA (N2) non-small cell lung cancer (NSCLC)
31. 43 β-Tubulin gene mutation-mediated paclitaxel resistance in non-small cell lung cancer (NSCLC)
32. 27 Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish lung cancer group
33. 43 β-Tubulin gene mutation-mediated paclitaxel resistance in non-small cell lung cancer (NSCLC)
34. 39 Six year follow up of the European Multicentre Randomised Study comparing Navelbine (NVB) alone vs NVB + Cisplatin (CDDP) vs Vindesine (VDS) + CDDP in 612 patients (pts) with advanced non-small cell lung cancer (NSCLC)
35. 27 Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish lung cancer group
36. 243 Spanish lung cancer group randomized trial of preoperative chemotherapy (cisplatin either 50 mg/m2 or 100 mg/m2) in stage IIIA (N2) non-small cell lung cancer (NSCLC)
37. 243 Spanish lung cancer group randomized trial of preoperative chemotherapy (cisplatin either 50 mg/m 2 or 100 mg/m 2) in stage IIIA (N2) non-small cell lung cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.